Form 4: Lenz Therapeutics CEO Evert B. Schimmelpennink Reports Stock Option Exercise

Evert B. Schimmelpennink, CEO of Lenz Therapeutics, exercised stock options to acquire 4,200 shares of common stock at $1.04 per share on March 7, 2025.

Summary

• On March 7, 2025, Evert B. Schimmelpennink, the CEO, President, and Secretary of Lenz Therapeutics, Inc., exercised stock options.
• He acquired 4,200 shares of common stock at a price of $1.04 per share.
• Following the transaction, Schimmelpennink directly owns 49,200 shares of common stock.
• He also directly owns 337,906 derivative securities in the form of stock options.
• The stock options were granted under the 2020 Equity Incentive Plan and vest over time, contingent on continued service.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a standard regulatory filing reflecting an insider transaction. It doesn't inherently indicate positive or negative news about the company's performance.

Positives

• The CEO's exercise of stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a continued commitment from the CEO.

Industry Context

This is a routine filing related to insider transactions. It's common for executives to receive and exercise stock options as part of their compensation packages, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants and vesting schedules are standard practice in the biotechnology industry to incentivize executives.
• Vesting schedules typically range from three to five years, with a common structure being 25% vesting after one year and then monthly vesting thereafter.
• The size of the option grant is relative to the executive's role and the company's overall equity compensation plan.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It provides transparency into executive compensation and ownership.

Key Dates